India, Oct. 29 -- By Shalini Bhardwaj

New Delhi [India], October 29 (ANI): The revised maximum retail price (MRP) list of non-scheduled anti-cancer drugs, effective from November 9, 2026, shows no change in the prices of major cancer drug formulations, including chemotherapy and immunotherapy medicines, offering no immediate price relief to patients purchasing these drugs.

The prices of several patented medicines used to treat lung cancer, breast cancer, blood cancer and bone marrow-related conditions remain unchanged.

Alectinib 150 mg, sold under the brand name Alecensa, continues to cost Rs. 4,30,696. Similarly, the price of Pembrolizumab 100 mg, an immunotherapy medicine marketed as Keytruda, remains at Rs. 2,16,500.

Osimertinib 80...